Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7910388rdf:typepubmed:Citationlld:pubmed
pubmed-article:7910388lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0029115lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0014597lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0025654lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0680727lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C1415804lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C1157594lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:7910388lifeskim:mentionsumls-concept:C0680242lld:lifeskim
pubmed-article:7910388pubmed:issue1lld:pubmed
pubmed-article:7910388pubmed:dateCreated1994-6-16lld:pubmed
pubmed-article:7910388pubmed:abstractTextThe functional activity of various 5-HT receptor agonists, including 5-CT, sumatriptan, CP 93, 129 and 1-naphtylpiperazine, and of drugs known to bind with high affinity to 5-HT1B (pindolol, propranolol, cyanopindolol, SDZ 21,009 and isamoltane) or 5-HT1D binding sites (yohimbine and rauwolscine) was measured at 5-HT receptors that are negatively coupled to adenylate cyclase in cultures of the renal epithelial cell line OK. 5-HT receptor-mediated inhibition of adenylate cyclase was studied by measuring inhibition of cAMP formation, induced by 100 microM forskolin. Besides 5-HT, various other compounds with affinity for 5-HT receptors behaved as agonists with the following rank order of potency: RU 24,969 > 5-CT > dihydroergotamine = 5-HT > CP 93,129 > d-LSD > 1-naphtylpiperazine > sumatriptan > TFMPP = mCPP > CGS 12066B = metergoline > methysergide. The beta-adrenergic receptor blockers cyanopindolol, SDZ 21,009, (-)-pindolol and (-)-propranolol, and the alpha 2-adrenergic blockers yohimbine and rauwolscine yielded agonist activity at nanomolar and micromolar concentrations, respectively. Isamoltane acted as a partial agonist. Methiothepin was the only compound that antagonised the OK cell 5-HT receptor-mediated inhibition of forskolin-induced cAMP formation. We conclude that the OK cell 5-HT receptor has properties consistent with a 5-HT1B receptor, although differences are apparent with regard to potencies of some compounds. Methiothepin is probably the only effective antagonist at 5-HT1B receptor sites, whereas the described putative 5-HT1B receptor antagonists have to be considered as partial agonists, yielding agonist or antagonist activity depending on the system that is studied.lld:pubmed
pubmed-article:7910388pubmed:languageenglld:pubmed
pubmed-article:7910388pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:citationSubsetIMlld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7910388pubmed:statusMEDLINElld:pubmed
pubmed-article:7910388pubmed:monthJanlld:pubmed
pubmed-article:7910388pubmed:issn0028-3908lld:pubmed
pubmed-article:7910388pubmed:authorpubmed-author:PauwelsP JPJlld:pubmed
pubmed-article:7910388pubmed:authorpubmed-author:PalmierCClld:pubmed
pubmed-article:7910388pubmed:issnTypePrintlld:pubmed
pubmed-article:7910388pubmed:volume33lld:pubmed
pubmed-article:7910388pubmed:ownerNLMlld:pubmed
pubmed-article:7910388pubmed:authorsCompleteYlld:pubmed
pubmed-article:7910388pubmed:pagination67-75lld:pubmed
pubmed-article:7910388pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:meshHeadingpubmed-meshheading:7910388-...lld:pubmed
pubmed-article:7910388pubmed:year1994lld:pubmed
pubmed-article:7910388pubmed:articleTitleInhibition by 5-HT of forskolin-induced cAMP formation in the renal opossum epithelial cell line OK: mediation by a 5-HT1B like receptor and antagonism by methiothepin.lld:pubmed
pubmed-article:7910388pubmed:affiliationLaboratory of Cellular Neurobiology, Centre de Recherche Pierre Fabre, Castres, France.lld:pubmed
pubmed-article:7910388pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7910388pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7910388lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7910388lld:pubmed